Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Assets data on file, last reported at $30.5 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $30.5 million, down 12.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.7 million (down 53.05% YoY), and the FY2025 annual result was $19.4 million, down 12.61% from the prior year.
• Non-Current Assets grew to $30.5 million in Q1 2026 per HBIO's latest filing, from $19.4 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $98.8 million in Q2 2022 and troughed at $19.4 million in Q4 2025.
• A 5-year average of $61.6 million and a median of $82.5 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets dropped 1.63% in 2022, then sank 59.52% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $30.0 million in 2022, then dropped by 17.98% to $24.6 million in 2023, then declined by 9.8% to $22.2 million in 2024, then decreased by 12.61% to $19.4 million in 2025, then jumped by 57.18% to $30.5 million in 2026.
• Business Quant data shows HBIO's Non-Current Assets at $30.5 million in Q1 2026, $19.4 million in Q4 2025, and $34.2 million in Q3 2025.